The aim of this technology assessment, which has been commissioned by NICE through the NIHR SR Programme as part of the NICE Single Technology Appraisal process, is to review the submission received from the Instituto Grifols on the clinical and cost-effectiveness evidence of Fostamatinib (Tavlesse®) for treating chronic immune thrombocytopenic purpura in adults. The primary source of clinical effectiveness evidence submitted by Instituto Grifols consists of two pivotal phase III RCTs (FIT1 and FIT2) assessing the efficacy and safety of Fostamatinib versus placebo. The Aberdeen HTA Group acts as the Evidence Review Group (ERG) for this technology appraisal and provides an independent critique of the clinical and cost-effectiveness evidence submitted by the company. Based on the findings of the submission received from the company and the ERG’s critique, NICE will release appropriate clinical guidance. For more information see: https://www.nice.org.uk/guidance/indevelopment/gid-ta10387
Contacts
- Miriam Brazzelli; m.brazzelli@abdn.ac.uk